<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114127</url>
  </required_header>
  <id_info>
    <org_study_id>2004-P-001384</org_study_id>
    <nct_id>NCT00114127</nct_id>
  </id_info>
  <brief_title>Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome</brief_title>
  <official_title>Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of duloxetine for the
      treatment of social anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An expanding body of clinical experience and controlled trials has established the efficacy
      of serotonin selective reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake
      inhibitor (SNRI) venlafaxine, for the treatment of social anxiety disorder, with paroxetine,
      sertraline and venlafaxine extended-release (XR), which are FDA approved for this indication.
      The newest SNRI, duloxetine, has been shown to be effective at doses of 60mg/day to 120mg/day
      for anxiety associated with depression, and is anticipated to be a broad spectrum agent for
      mood and anxiety disorders (Dunner, Goldstein, Mallinckrodt, Lu, &amp; Detke, 2003). However, no
      data on the efficacy of duloxetine for Social Anxiety Disorder, nor guidance regarding time
      to response or predictors of response, is yet available. These questions are the focus of
      this proposal.

      This is a two phase, 24-week research study in which participants who remain symptomatic at
      the end of one phase (6 weeks) enter into the next phase. In phase I, all participants
      receive 60mg/day of duloxetine (Cymbalta) for 6 weeks. Participants who continue to have
      anxiety symptoms will enter the 18-week Phase II, in which they continue taking 60 mg/day of
      duloxetine and they will also be randomly assigned (by chance, like a flip of a coin) to
      receive either an additional 60mg/day of duloxetine or placebo (contains no active
      medication).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale</measure>
    <time_frame>6 months</time_frame>
    <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety. The LSAS contains three total scores: 1) total fear score (0-72), 2) total avoidance score(0-72), 3) and total overall score (0-144). Suggested interpretations: 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, Greater than 95 - Very severe social phobia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>6 months</time_frame>
    <description>The Clinician Global Impression-Severity Scale (CGI-S) is a clinician-rated instrument used to assess global severity of symptoms (Guy, 1976). The CGI ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Baseline collected for Phase 1 at week 0 and for Phase 2 at week 6.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Duloxetine 60mg + Placebo for 18 Weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 120mg for 18 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 60mg/day for 6 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Phase 1 all participants entered an open trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>60 mg duloxetine 1x per day</description>
    <arm_group_label>Duloxetine 60mg + Placebo for 18 Weeks</arm_group_label>
    <arm_group_label>Duloxetine 60mg/day for 6 Weeks</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>60 mg duloxetine 1x per day + 60mg duloxetine 1x per day</description>
    <arm_group_label>Duloxetine 120mg for 18 Weeks</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>60mg placebo 1x per day</description>
    <arm_group_label>Duloxetine 60mg + Placebo for 18 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients &gt; 18 years of age with a primary psychiatric diagnosis of
             generalized social anxiety disorder as defined by DSM-IV criteria and an LSAS score &gt;
             50.

          -  Physical examination, electrocardiogram, and laboratory findings without clinically
             significant abnormalities.

          -  Willingness and ability to comply with the requirements of the study protocol.

        Exclusion Criteria:

          -  Patient has a history of intolerance or lack of response to a treatment trial of
             duloxetine at highest tolerated dose (&lt;120mg/day).

          -  Patients with acute narrow angle glaucoma.

          -  Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier
             devices, condoms and foam, or implanted progesterone rods stabilized for at least 3
             months).

          -  Concurrent use of other psychotropic medications. Patients must discontinue regular
             benzodiazepine or antidepressant therapy at least one week (5 weeks for fluoxetine)
             prior to baseline. Concomitant beta-blockers are proscribed unless prescribed for a
             medical indication (e.g., hypertension, at a stable daily dose for &gt; 1 month).

          -  Patients with a history of failure to satisfactorily respond to &gt;2 prior adequate
             treatment trials.

          -  Significant personality dysfunction likely to interfere with study participation.

          -  Serious medical illness or instability for which hospitalization may be likely within
             the next year.

          -  Seizure disorders with the exception of a history of febrile seizures if they occurred
             during childhood, were isolated, and did not recur in adulthood.

          -  Concurrent psychotherapy initiated within 2 months of baseline is prohibited. Ongoing
             psychotherapy of any duration directed specifically toward treatment of the social
             anxiety disorder is excluded. Prohibited psychotherapy includes cognitive behavioral
             therapy or psychodynamic therapy that focuses on exploring specific, dynamic causes of
             the phobic symptomatology and provides skills for their management. General supportive
             individual, couples, or family therapy greater than 2 months duration is acceptable.

          -  Diagnosis of any of the following mental disorders as defined by the DSM-IV: a
             lifetime history of schizophrenia or any other psychosis, mental retardation, organic
             medical disorders or bipolar disorder; eating disorders in the past 6 months; alcohol
             or substance abuse in the past 3 months or dependence within the past 6 months.

          -  Entry of patients with major depression, dysthymia, panic disorder, generalized
             anxiety disorder, post-traumatic stress disorder or obsessive-compulsive disorder will
             be permitted if the social anxiety disorder is judged to be the predominant disorder,
             in order to increase accrual of a clinically relevant sample.

          -  Patients with significant suicidal ideation (MADRS item 10 score &gt; 3) or who have
             enacted suicidal behaviors within 6 months prior to intake will be excluded from study
             participation and referred for appropriate clinical intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi M Simon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mghanxiety.org</url>
    <description>Official Website for the Center for Anxiety and Traumatic Stress Disorders</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <results_first_submitted>January 27, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2012</results_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Naomi M. Simon</investigator_full_name>
    <investigator_title>Director, Center for Anxiety and Traumatic Stress Disorders</investigator_title>
  </responsible_party>
  <keyword>social anxiety disorder</keyword>
  <keyword>social phobia</keyword>
  <keyword>duloxetine</keyword>
  <keyword>serotonin norepinephrine reuptake inhibitor</keyword>
  <keyword>SNRI</keyword>
  <keyword>double blind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Treatment seeking outpatients aged 18 years and older with a primary diagnosis of Generalized Social Anxiety Disorder (GSAD) were recruited by media advertisement.</recruitment_details>
      <pre_assignment_details>Of the 39 participants who completed Phase I of this study, 28 moved on to Phase II.
1 subject was lost to follow up between baseline and week 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 13 received 60mg duloxetine plus placebo for 18 additional weeks.</description>
        </group>
        <group group_id="P2">
          <title>Duloxetine 120mg/Day for 18 Weeks (Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 15 received 120mg duloxetine for 18 additional weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine 60mg/Day + Placebo for 18 Weeks(Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 13 received 60mg duloxetine plus placebo for 18 additional weeks.</description>
        </group>
        <group group_id="B2">
          <title>Duloxetine 120mg/Day for 18 Weeks (Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 15 received 120mg duloxetine for 18 additional weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="14.2"/>
                    <measurement group_id="B2" value="35.5" spread="11.6"/>
                    <measurement group_id="B3" value="36" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational status, college graduate</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>College Graduate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not College Graduate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of illness, mean years (SD)</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="17.0"/>
                    <measurement group_id="B2" value="20.1" spread="12.3"/>
                    <measurement group_id="B3" value="23.7" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset, mean age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="3.3"/>
                    <measurement group_id="B2" value="13.9" spread="8.1"/>
                    <measurement group_id="B3" value="12.0" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current comorbidity, Major depressive disorder (MDD)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Comorbid MDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Comorbid MDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current comorbidity, Dysthymia</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Comorbid Dysthymia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Comorbid Dysthymia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current comorbidity, Panic Disorder (PD)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Comorbid PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Comorbid PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current comorbidity, Generalized anxiety disorder (GAD)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Comorbid GAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Comorbid GAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At least one concurrent mood or anxiety disorder</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Concurrent mood or anxiety disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No concurrent mood or anxiety disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime depression</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lifetime depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Lifetime depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime alcohol or substance abuse or dependence</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lifetime Alcohol/substance abuse/dependence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Lifetime Alcohol/substance abuse/dependence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liebowitz Social Anxiety Scale (LSAS)</title>
          <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety (55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, Greater than 95 - Very severe social phobia). It is widely used in treatment studies of SAD. The instrument shows very good psychometric properties (Heimberg et al., 1999; Safren et al., 1999).
Baseline collected for Phase 1 at week 0 and for Phase 2 at week 6.</description>
          <units>LSAS Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.2" spread="6.90"/>
                    <measurement group_id="B2" value="74.1" spread="6.20"/>
                    <measurement group_id="B3" value="74.6" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression-Severity (CGI-S)</title>
          <description>The Clinician Global Impression-Severity Scale (CGI-S) is a clinician-rated instrument used to assess global severity of symptoms (Guy, 1976). The CGI ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Baseline collected for Phase 1 at week 0 and for Phase 2 at week 6.</description>
          <units>CGI-S Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.10" spread="0.43"/>
                    <measurement group_id="B2" value="4.93" spread="0.36"/>
                    <measurement group_id="B3" value="5.00" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression-Improvement (CGI-I)</title>
          <description>The Clinician Global Impression-Improvement Scale (CGI-I) is a clinician-rated instrument used to assess global improvement of symptoms (Guy, 1976). The CGI ranges from 1 (very much improved) to 7 (very much worse).
Baseline CGI-I was not collected in Phase 1 as it is a measure of improvement. Baseline CGI-I was collected in Phase 2 because patients were transitioning from week 6 to 7.</description>
          <units>CGI-I Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25" spread="0.97"/>
                    <measurement group_id="B2" value="3.36" spread="1.22"/>
                    <measurement group_id="B3" value="3.31" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>MADRS; Montgomery &amp; Asberg, 1979. The MADRS is designed to measure the overall severity of depressive symptoms and has demonstrated good reliability and sensitivity to change with treatment. It includes 10 items and uses a 0-6 severity scale with higher scores indicating increasing depressive symptoms. Ratings can be added to form an overall score (range 0 to 60); no weights are used. Cut-off points include: 0 to 6 – symptom absent, 7 to 19 – mild depression, 30 to 34 – moderate, 35 to 60 – severe depression.
Baseline MADRS only collected in Phase 2 at week 6.</description>
          <units>MADRS Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.08" spread="5.00"/>
                    <measurement group_id="B2" value="10.3" spread="7.79"/>
                    <measurement group_id="B3" value="9.17" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sheehan Disability Scale (SDS)</title>
          <description>The SDS is a brief self-report questionnaire that was developed to assess functional impairment in three inter-related domains; work/school, social and family life. The patient rates the extent to which work/school, social and family responsibilities are impaired by his/her symptoms on a 10 point visual analog scale. The three items are summed into a single dimension measure of global function impairment that ranges from 0 (unimpaired) to 30 (highly impaired).
Baseline SDS only collected in Phase 2 at week 6.</description>
          <units>SDS Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="6.06"/>
                    <measurement group_id="B2" value="14.1" spread="5.52"/>
                    <measurement group_id="B3" value="12.9" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</title>
          <description>Q-LES-Q; Endicott et al., 1993. This questionnaire rates 16 aspects of quality of life, including physical health, mood, activities of daily living, and overall life satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70, with higher scores indicating higher satisfaction with quality of life.
Baseline QLESQ only collected in Phase 2 at week 6.</description>
          <units>Q-LES-Q Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="8.83"/>
                    <measurement group_id="B2" value="46.2" spread="9.47"/>
                    <measurement group_id="B3" value="47.5" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liebowitz Self-Rated Disability Scale (LSDSR)</title>
          <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety. The LSAS contains three total scores: 1) total fear score (0-72), 2) total avoidance score(0-72), 3) and total overall score (0-144). Suggested interpretations: 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, Greater than 95 - Very severe social phobia.
Baseline was only collected for Phase 2 at week 6</description>
          <units>LSDSR Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.58" spread="6.43"/>
                    <measurement group_id="B2" value="10.0" spread="5.41"/>
                    <measurement group_id="B3" value="8.79" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale</title>
        <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety. The LSAS contains three total scores: 1) total fear score (0-72), 2) total avoidance score(0-72), 3) and total overall score (0-144). Suggested interpretations: 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, Greater than 95 - Very severe social phobia.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)</title>
            <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 13 received 60mg duloxetine plus placebo for 18 additional weeks.</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 120mg/Day for 18 Weeks (Phase 2)</title>
            <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 15 received 120mg duloxetine for 18 additional weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale</title>
          <description>The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety. The LSAS contains three total scores: 1) total fear score (0-72), 2) total avoidance score(0-72), 3) and total overall score (0-144). Suggested interpretations: 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, Greater than 95 - Very severe social phobia.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="7.60"/>
                    <measurement group_id="O2" value="53.7" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.132</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-S</title>
        <description>The Clinician Global Impression-Severity Scale (CGI-S) is a clinician-rated instrument used to assess global severity of symptoms (Guy, 1976). The CGI ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Baseline collected for Phase 1 at week 0 and for Phase 2 at week 6.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)</title>
            <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 13 received 60mg duloxetine plus placebo for 18 additional weeks.</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 120mg/Day for 18 Weeks (Phase 2)</title>
            <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 15 received 120mg duloxetine for 18 additional weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-S</title>
          <description>The Clinician Global Impression-Severity Scale (CGI-S) is a clinician-rated instrument used to assess global severity of symptoms (Guy, 1976). The CGI ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Baseline collected for Phase 1 at week 0 and for Phase 2 at week 6.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="0.48"/>
                    <measurement group_id="O2" value="3.60" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.292</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine 60mg/Day + Placebo for 18 Weeks (Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 13 received 60mg duloxetine plus placebo for 18 additional weeks.</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine 120mg/Day for 18 Weeks (Phase 2)</title>
          <description>Participants who did not achieve remission at the end of Phase 1 entered Phase 2 and were randomized. 15 received 120mg duloxetine for 18 additional weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Tests</sub_title>
                <description>The elevated LFTs were later diagnosed by primary care physician on evaluation as unrelated to study medication and a result of rhabdomyolysis from a week of intensive weight lifting and exercises.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Study medication overdose</sub_title>
                <description>The study medication overdose was in the context of alcohol use and suicidal ideation and had no medical consequences: this was deemed possibly related to duloxetine and the participant was transferred to clinical care.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation and other side effects</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased drinking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open-label in phase Phase 1; Limited power due to small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Naomi Simon</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-7913</phone>
      <email>nsimon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

